VBLT Vascular Biogenics Ltd. - Ordin

4.95
-0.1  -1.98%
Previous Close 5.05
Open 5.00
Price To book 2.91
Market Cap 133.03M
Shares 26,875,000
Volume 69,229
Short Ratio 2.00
Av. Daily Volume 134,213

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial previously met primary endpoint. Overall survival data released November 29, 2016.
VB-111
Thyroid cancer
Phase 3 trial to be initiated 2H 2017.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due mid 2017. Full data due early 2018.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis

Latest News

  1. VBL Therapeutics Provides Year End 2016 Corporate Update
  2. VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
  3. VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
  4. How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers
  5. VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
  6. Vascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  7. VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer
  8. VBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
  9. VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
  10. VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
  11. VBL Therapeutics to Report Third Quarter 2016 Financial Results on November 10
  12. VBL Therapeutics to Report Third Quarter 2016 Financial Results on November 10
  13. VBL Therapeutics Announces Plans to Establish New Manufacturing Facility
  14. Earnings Estimates Moving Higher for Vascular Biogenics (VBLT): Time to Buy?
  15. 5 Stocks Under $10 That Could Make You a Lot of Money
  16. VBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update
  17. BioLineRx Names Philip A. Serlin as Chief Executive Officer
  18. BioLineRx Names Philip A. Serlin as Chief Executive Officer
  19. VBL Therapeutics to Report Second Quarter 2016 Financial Results on August 15
  20. Trade These 7 Stocks Under $10 for Huge Profits